Apartment sales rise in April, Hapoalim says

The index is based on four parameters, including mortgages, apartment prices, income and unemployment.

By MATTHEW KRIEGER
May 24, 2007 06:48

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Bank Hapoalim's apartment sales index rose 2.2 percent in April to 151.3 points, the bank reported this week. Since the beginning of the year, the index, which measures the strength of the apartment sales market, has risen 4.9%. The index is based on four parameters, including mortgages, apartment prices, income and unemployment. The bank reported that interest on mortgages has fallen 0.11%, while prices of apartments have decreased 1.4%. Average income per month in the country currently stands at NIS 7,473 and the level of unemployment is now at 7.6%, Hapoalim said in its monthly report.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS